ESSA Pharma Inc
(TSX Venture Exchange : EPIX)

( )
EPIX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.05%42.410.9%$1199.87m
JNJJohnson & Johnson
1.54%136.380.6%$1051.14m
MRKMerck & Co., Inc.
1.14%79.840.6%$996.51m
BMYBristol-Myers Squibb Company
1.59%51.641.4%$763.48m
LLYEli Lilly and Company
1.41%122.451.0%$755.53m
ABBVAbbVie, Inc.
0.40%80.842.2%$698.69m
NVONovo Nordisk A/S Sponsored ADR Class B
1.15%50.350.1%$71.06m
SNYSanofi Sponsored ADR
2.38%42.550.2%$38.74m
LCILannett Company, Inc.
4.92%9.8137.0%$16.82m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.11%1.851.7%$0.06m
EPIXESSA Pharma Inc
3.88%3.750.1%$0.05m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.